Table 4.
Comparison of the treatment profile of 4 groups
| Clinical variables | Mean (SD)/n (%) | Chi-square value (P) | ||||
|---|---|---|---|---|---|---|
| Whole sample (n=844) | Group I No residual symptoms (HDRS and YMRS=0) (n=175) | Group II Only depressive residual symptoms (YMRS =0 and HDRS=1-7) (n=170) | Group III Only manic symptoms (HDRS=0 and YMRS >1-7) (n=88) | Group IV Both depressive and manic symptoms (both HDRS and YMRS >1-7) (n=411) | ||
| MS + AP | 342 (40.5) | 70 (40.0) | 49 (28.8) | 37 (42.0) | 186 (45.3) | 13.578 (0.004)** |
| MS + AD | 97 (11.5) | 13 (7.4) | 36 (21.2) | 6 (6.8) | 42 (10.2) | 21.06 (<0.001)*** |
| MS + AD + AP | 63 (7.5) | 5 (2.9) | 11 (6.5) | 2 (2.3) | 45 (10.9) | 16.280 (0.001)*** |
| MS only | 310 (36.7) | 82 (46.9) | 61 (35.9) | 40 (45.5) | 127 (30.9) | 16.669 (0.001)*** |
| AP only | 22 (2.6) | 5 (2.9) | 8 (4.7) | 3 (3.4) | 6 (1.5) | 5.347 (0.148) |
| AP + AD | 10 (1.2) | 0 (0) | 5 (2.9) | 0 (0) | 5 (1.2) | 7.636 (0.054) |
| Antipsychotics | ||||||
| None | 407 (48.2) | 95 (54.3) | 97 (57.1) | 46 (52.3) | 169 (41.1) | 16.77 (0.0007)*** |
| Olanzapine | 273 (32.3) | 48 (27.4) | 33 (19.4) | 22 (25) | 170 (41.4) | 32.36 (<0.001)*** |
| Risperidone | 57 (6.8) | 14 (8.0) | 13 (7.6) | 9 (10.2) | 21 (5.1) | 4.09 (0.251) |
| Quetiapine | 68 (8.1) | 11 (6.3) | 19 (11.2) | 5 (5.7) | 33 (8.0) | 3.645 (0.302) |
| Aripiprazole | 14 (1.7) | 4 (2.3) | 1 (0.6) | 2 (2.3) | 7 (1.7) | 1.824 (0.609) |
| Ziprasidone | 1 (0.1) | 0 (0) | 0 (0) | 0 (0) | 1 (0.2) | - |
| Clozapine | 7 (0.8) | 1 (0.6) | 2 (1.2) | 3 (3.4) | 1 (0.2) | 9.227 (0.026)* |
| Lurasidone | 1 (0.1) | 0 (0) | 0 (0) | 0 (0) | 1 (0.2) | - |
| Trifluoperazine | 13 (1.5) | 1 (0.6) | 4 (2.4) | 1 (1.1) | 7 (1.7) | 1.99 (0.574) |
| Chlorpromazine | 3 (0.4) | 1 (0.6) | 1 (0.6) | 0 (0) | 1 (0.2) | - |
| Antidepressants | ||||||
| None | 674 (79.9) | 157 (89.7) | 118 (69.4) | 80 (90.9) | 319 (77.6) | 30.068 (<0.001)*** |
| Escitalopram | 34 (4.0) | 2 (1.1) | 12 (7.1) | 1 (1.1) | 19 (4.6) | 10.086 (0.017)* |
| Sertraline | 18 (2.1) | 5 (2.9) | 5 (2.9) | 1 (1.1) | 7 (1.7) | 1.754 (0.624) |
| Fluoxetine | 22 (2.6) | 2 (1.1) | 3 (1.8) | 3 (3.4) | 14 (3.4) | 3.210 (0.360) |
| Paroxetine | 11 (1.3) | 0 (0) | 0 (0) | 0 (0) | 11 (2.7) | - |
| Venlafaxine | 23 (2.7) | 1 (0.6) | 9 (5.3) | 1 (1.1) | 12 (2.9) | 8.191 (0.042)* |
| Mirtazapine | 26 (3.1) | 0 (0) | 9 (5.3) | 0 (0) | 17 (4.1) | - |
| Bupropion | 29 (3.4) | 6 (3.4) | 12 (7.1) | 1 (1.1) | 10 (2.4) | 9.373 (0.024)* |
| Amitriptyline | 7 (0.8) | 2 (1.1) | 2 ( 1.2) | 1 (1.1) | 2 (0.5) | 1.146 (0.765) |
| Mood stabilizers | ||||||
| None | 32 (3.8) | 5 (2.9) | 13 (7.6) | 3 (3.4) | 11 (2.7) | 8.783 (0.032)* |
| Lithium | 518 (61.4) | 114 (65.1) | 91 (53.5) | 45 (51.1) | 268 (65.2) | 11.899 (0.007)** |
| Valproate | 241 (28.6) | 46 (26.3) | 57 (33.5) | 24 (27.3) | 114 (27.7) | 2.709 (0.438) |
| Carbamazepine | 9 (1.1) | 1 (0.6) | 2 (1.2) | 2 (2.3) | 4 (1.0) | 1.673 (0.642) |
| Lithium + valproate | 39 (4.6) | 9 (5.1) | 6 (3.5) | 14 (15.9) | 10 (2.4) | 30.473 (<0.001)*** |
| Lamotrigine | 5 (0.6) | 0 (0) | 1 (0.6) | 0 (0) | 4 (1.0) | - |
*P<0.05; **P<0.01; ***P<0.001. MS – Mood stabilizers; AP – Antipsychotics; AD – Antidepressants; YMRS – Young Mania Rating Scale; HDRS – HDRS – Hamilton Depression Rating Scale; SD – Standard deviation